AI Stock Memo: SRPT - Sarepta Therapeutics - RankAlpha

SRPT

Rating neutralTentativeAI Memo

Sarepta Therapeutics

As of 2026-04-12/Confidence medium/Horizon 3m

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-04-12 • Model: RankAlpha Sentiment AI

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Report quality notice

peer set is too generic or lacks enough direct operating comparators

Action

neutral

Confidence

medium

Horizon

Key catalyst

Next quarterly report / 10-Q (monitor for guidance and cash/runway commentary) • 2026-07-11

Expected move: +34%

Biggest risk

Bear case assumes disappointing safety/readout follow-ups or worsening cash-runway commentary in the next quarterly filing, driving re-rating into mid-teens or single-digit multiples.

Invalidation

Break below $12 or thesis failure.

What would change my mind?

Bull case assumes positive program-specific safety/efficacy updates and clearer commercial traction for approved/skilled-access products, pushing multiples toward peer medians and supporting >80% upside vs. anchor.

Research note

Recommendation

neutral

Confidence

medium

As of

2026-04-12

Base target

$24

p=50%

Bull target

$40

p=25%

Bear target

$12

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Next quarterly report / 10-Q (monitor for guidance and cash/runway commentary)
Pipeline/safety follow-up from recent presentations and program updates
Bull case assumes positive program-specific safety/efficacy updates and clearer commercial traction for approved/skilled-access products, pushing multiples toward peer medians and supporting >80% upside vs.

BearKey bullets

Clinical/safety setbacks in gene-therapy programs
Commercial adoption and payer access delays
Worsening cash runway or need for dilutive financing

WatchKey bullets

ANCHOR: {"price": 21.18, "timestamp_utc": "2026-04-10T00:00:00Z", "source": "rankalpha_api_adj_close"} ANALYST_TARGETS_REVIEWED: true Analyst median target (23.64) sits near our base target; our base (24.0) is close to the analyst median while our bull/bear span the market's high/low dispersion (analyst low 10, high 80) and reflect event-driven upside/downside scenarios [#SERP-1] [#SERP-2].

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $24 (p=50%)

Bull/Bear spread: +124% / -33%

Vs latest close: Bull +124% · Base +34% · Bear -33%

Scenario probabilities

Bull Target: $40 (p=25%)Base Target: $24 (p=50%)Bear Target: $12 (p=25%)

Commentary

Market tone is mixed: analyst consensus leans toward 'Hold' with a wide target spread, reflecting event-driven binary outcomes for Sarepta's programs [#SERP-1]. Recent SEC filings (10-K, 8-K) provide routine disclosure but limited fresh forward guidance, keeping near-term sentiment cautious [#10-K-2026-03-02] [#8-K-2026-02-25].

As of 2026-04-12 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Bear case assumes disappointing safety/readout follow-ups or worsening cash-runway commentary in the next quarterly filing, driving re-rating into mid-teens or single-digit multiples.

Drivers

Scannable catalysts and supporting factors

Next quarterly report / 10-Q (monitor for guidance and cash/runway commentary)
Pipeline/safety follow-up from recent presentations and program updates

Human Analyst Targets

External snippets for comparison only; verify at source.

Unverified externalLast fetched 2026-04-12Source quality: external scrape

External snippets are unverified; treat as directional signals only. Always confirm with the original provider.

Inline RA est

Provider

serper

Median (USD)

$23.64

Range (USD)

$10.00 - $80.00

Count

Query: Sarepta Therapeutics Inc Common (SRPT) analyst consensus price target high low average

Sarepta (SRPT) Stock Forecast & Price Target - Investing.com
Search result #1
According to projections from 23 analysts, the average 12-month price target for Sarepta is 21.70 USD, with a high estimate of 38 USD and a low estimate of ...
Extracted: $21.70, $38.00Open source
Sarepta Therapeutics, Inc.: Target Price Consensus and Analysts ...
Search result #2
Analysts' Consensus ; Mean consensus. HOLD ; Number of Analysts. 25 ; Last Close Price. 23.08USD ; Average target price. 21.70USD ; Spread / Average Target. -6.00%.
Extracted: $23.08, $21.70Open source
SRPT Price: Quote, Forecast, Charts & News - Perplexity
Search result #4
... price target hike. Analyst sentiment remains divided, with a consensus "Hold" and average target of $32.30 — well above current levels — as ...
Extracted: $32.30Open source4 days ago
SRPT Forecast, Price Target & Analyst Ratings - ChartMill
Search result #6
33 Wall Street analysts provided a forecast for the next 12 months for SRPT. The average price target is 30.27 USD. This implies a price increase of 32.77% is ...
Extracted: $30.27Open source
Sarepta Therapeutics SRPT - Analyst Price Targets & Ratings History
Search result #7
Highest price target for SRPT is $80, Lowest price target is $10, average price target is $23.64. Most recent stock forecast was given by YIGAL NOCHOMOVITZ from ...
Extracted: $80.00, $10.00, $23.64Open source
SRPT Stock Forecast 2026 - Sarepta Price Targets & Predictions
Search result #9
Based on our analysis of 44 Wall Street analysts, SRPT has a neutral consensus with a median price target of $20.00 (ranging from $5.00 to $38.00). The overall ...
Extracted: $20.00, $5.00, $38.00Open source

Scenarios

Bull Target (Scenario probability)

$40 / p=25% prob

Base Target (Scenario probability)

$24 / p=50% prob

Bear Target (Scenario probability)

$12 / p=25% prob

Price $18 as of 2026-05-29

Nearest Scenario: Bear (∆ 33%)

Targets vs latest close: Bull +124% · Base +34% · Bear -33%

Sentiment & Exposure

Sentiment unavailable: insufficient coverage

Short-term Catalysts

Next few weeks

Next quarterly report / 10-Q (monitor for guidance and cash/runway commentary)
2026-07-11
Market reaction to Sarepta's next quarterly report (Q1 2026 / 10-Q/earnings) could drive share moves; prior cadence and disclosures shown in the 2025 10-Q and 2025 10-K set the baseline for monitoring revenue, royalty disclosures and program updates [#10-Q-2025-11-06] [#10-K-2026-03-02].
Prob 75% • Move 12% • Priced-in 40%

Long-term Catalysts

Months to a year

Pipeline/safety follow-up from recent presentations and program updates
2026-12-31
Sarepta indicated presentations of long-term and safety data across gene therapy and exon-skipping programs in its IR materials; further company-updated safety/efficacy follow-ups or regulatory interactions through 2026 would materially re-rate prospects for lead programs [#IR-undated] [#8-K-2026-02-25].
Prob 50% • Move 30% • Priced-in 25%

Risks

Clinical/safety setbacks in gene-therapy programs
Commercial adoption and payer access delays
Worsening cash runway or need for dilutive financing

Peers

Symbol	Summary
RARE	Ultragenyx — rare-disease specialist with comparable orphan-program commercialization and regulatory-readout risk profile.
VRTX	Vertex — leader in genetic therapies; useful comparator for program-stage gene-therapy commercialization trajectories.
GILD	Gilead — larger antiviral/biotech with recent gene-therapy investments; serves as a commercial-scale comparator for later-stage launches and supply-chain execution.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment AI
Human targets: serper
Targets query: Sarepta Therapeutics Inc Common (SRPT) analyst consensus price target high low average
Analysis date: 2026-04-12